Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designsResearch in context

• Autores principales: Fredi Alexander Diaz-Quijano (Autor), Denise Siqueira de Carvalho (Autor), Sonia Mara Raboni (Autor), Silvia Emiko Shimakura (Autor), Angela Maron de Mello (Autor), Magda Clara Vieira da Costa-Ribeiro (Autor), Lineu Silva (Autor), Marilene da Cruz Magalhães Buffon (Autor), Eliane Mara Cesario Pereira Maluf (Autor), Gabriel Graeff (Autor), Gustavo Almeida (Autor), Clara Preto (Autor), Karin Regina Luhm (Autor)
• Formato: Libro
• Publicado: Elsevier, 2024-07-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Summary: Background: CYD-TDV (Dengvaxia®) was the first dengue vaccine approved, launched in Brazil in 2015 for individuals aged 9-44 years. We aimed to estimate the effectiveness of CYD-TDV in preventing symptomatic dengue cases during a campaign targeting individuals aged 15-27 years in selected m...